Financial News
Week in Review: BeiGene Signs $2.2 Billion Deal with Novartis for PD-1
By:
ChinaBio® Today
January 16, 2021 at 04:22 AM EST
Deals and Financings Beijing 's BeiGene out-licensed ex-China rights for its China-approved anti-PD-1 antibody to Novartis in a $2.2 billion agreement, including a $650 million upfront payment; Shanghai 's Inmagene in-licensed global rights to four novel pre-clinical immunological molecules from Chi-Med in a $920 million deal; CICC Capital announced its RMB biomedical private equity fund, CICC Qide, raised $648 million as of the second closing; EQRx, a Cambridge, MA biopharma that aims to cut US drug prices by 50% or more, completed a $500 million funding for its portfolio that includes three China-sourced candidates; BeiGene announced a $310 million agreement for China/Asia rights to an mRNA treatment developed by Strand Therapeutics for solid tumor cancers; EOC Pharma, the Shanghai oncology arm of Eddingpharm, acquired China rights to an mTOR inhibitor from Aadi Bioscience in a $271 million agreement; Shanghai 's Visen Pharma closed a $150 million Series B financing to develop novel endocrine drugs in a round led by Sequoia China ; Shanghai Henlius Biotech announced a $122.5 million agreement for rights to two anti-TPOR-2 antibodies from Chiome Bioscience of Japan ; Shenzhen Raysight Medical completed a $46 million Series B funding for its clinical real-time monitoring systems to provide early warnings of heart disease; Industry Insights In 2020, investment in China life science showed stellar growth. ChinaBio®'s survey shows four of the five investment categories set new records, often doubling the year-earlier result, while the fifth, M&A, fell for the second year in a row; China 's biopharma industry continued to grow at a rapid pace in 2020, in spite of COVID-19 disruption according to panelists at the China Showcase; Trials and Approvals Gracell Biotech of Suzhou was approved to start a China Phase I/II clinical trial of its donor-derived CD19 CAR-T cell therapy. Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ/AIM: HCM) (HK: 2696) (NSDQ: GRCL) Share this with colleagues: // //
Related Stocks:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.